AI reads MRIs to spot dangerous prostate cancers without a needle
NCT ID NCT06842264
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aims to develop and test an AI model that analyzes prostate MRI scans to predict whether a cancer is aggressive (clinically significant). Researchers will use data from 3,000 patients who had both an MRI and a biopsy. The goal is to create a tool that helps doctors decide who really needs a biopsy, reducing unnecessary procedures.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to a more accurate, non-invasive way to predict aggressive prostate cancer, potentially reducing the need for biopsies.
What could go wrong
This is an observational study using existing data, so it cannot prove the AI model works in real-time. The results may not apply to all patients or hospitals.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Peking University First Hospital
RECRUITINGBeijing, 100034, China